Grifols completes cohort 1 in study of Alpha-1 15%

Grifols announced that it has completed Cohort 1 of its Phase 1/2 study evaluating Alpha1-Proteinase Inhibitor Subcutaneous 15%, a subcutaneous alpha antitrypsin treatment being compared to Liquid Alpha1-Proteinase Inhibitor intravenous. In this multi-center, single-dose and repeat-dose study over eight weeks, Cohort 1 has been completed and demonstrated no safety issues with Alpha-1 15% that would prevent the study from moving forward into Cohort 2. “A subcutaneous option would be a first for alpha-1 patients, providing more freedom when it comes to managing their AAT deficiency by allowing patients to administer their medication from the comfort of their own home. We are pleased to announce this milestone during Alpha-1 Awareness Month, contributing to raising further visibility about this rare disease,” said Jorg Schuttrumpf, Chief Scientific Innovation Officer, Grifols. “We look forward to moving this study into Cohort 2. Grifols has a strong commitment to the alpha-1 community and continues to innovate to find additional treatment options for patients living with this disease, in addition to more convenient alpha-1 testing alternatives such as AlphaID(TM) At Home, our recently launched direct-to-consumer genetic health risk service.”